Please Wait.....
Report
Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Industry Report I 2022-04-29 I 330 Pages I Global Markets Direct
Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Drugs In Development, 2022, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.
Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 34, 21, 27, 3, 38, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.
Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dyslipidemia - Overview
Dyslipidemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dyslipidemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dyslipidemia - Companies Involved in Therapeutics Development
Dyslipidemia - Drug Profiles
Dyslipidemia - Dormant Projects
Dyslipidemia - Discontinued Products
Dyslipidemia - Product Development Milestones
Featured News & Press Releases
Feb 25, 2022: Arrowhead concludes enrolment in Phase IIb mixed dyslipidemia trial
Dec 22, 2021: Akeso: Early completion of patient enrollment of Ebronucimab (PCSK9 monoclonal antibody, AK102) in a phase III clinical trial for primary hypercholesterolemia and mixed hyperlipidemia in China
Nov 15, 2021: Arrowhead presents new clinical data on ARO-APOC3 at AHA 2021
Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial
Nov 03, 2021: Ionis begins clinical trial of severe hypertriglyceridemia medicine
Nov 02, 2021: Rivus reports positive data from trial of cardiometabolic disease therapy
Sep 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of ARO-APOC3 for treatment of mixed dyslipidemia
Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins
Jul 06, 2021: Novartis announces complete response resubmission for inclisiran new drug application
Jun 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-ANG3 for treatment of mixed dyslipidemia
Jun 03, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-APOC3 for treatment of severe hypertriglyceridemia
May 16, 2021: tctMD: Evinacumab lowers triglycerides in severe hypertriglyceridemia
Mar 22, 2021: JW Pharmaceutical: Proving the effect of improving lipids as a result of phase 3 clinical trial of RivaroJet 'NDA application'
Mar 01, 2021: Arrowhead Pharmaceuticals files IND to begin phase 2b study of ARO-APOC3 in patients with severe hypertriglyceridemia
Feb 01, 2021: Matinas BioPharma announces topline results from ENHANCE-IT study of LYPDISO against Vascepa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dyslipidemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dyslipidemia - Pipeline by 89bio Inc, 2022
Dyslipidemia - Pipeline by ABIONYX Pharma SA, 2022
Dyslipidemia - Pipeline by Addpharma Inc, 2022
Dyslipidemia - Pipeline by Afimmune Biopharma Ltd, 2022
Dyslipidemia - Pipeline by Akcea Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Akeso Inc, 2022
Dyslipidemia - Pipeline by Amarin Corp Plc, 2022
Dyslipidemia - Pipeline by Arrakis Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by AstraZeneca Plc, 2022
Dyslipidemia - Pipeline by AVVA Pharmaceuticals AG, 2022
Dyslipidemia - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Dyslipidemia - Pipeline by Bio-Thera Solutions Ltd, 2022
Dyslipidemia - Pipeline by BioRestorative Therapies Inc, 2022
Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Cardax Inc, 2022
Dyslipidemia - Pipeline by Celltrion Inc, 2022
Dyslipidemia - Pipeline by Centaurus Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Centeer BioTherapeutics Ltd Co, 2022
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Dyslipidemia - Pipeline by CMG Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Corvidia Therapeutics Inc, 2022
Dyslipidemia - Pipeline by CVI Pharmaceuticals US Inc, 2022
Dyslipidemia - Pipeline by Daewon Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Daiichi Sankyo Co Ltd, 2022
Dyslipidemia - Pipeline by Delivra Corp, 2022
Dyslipidemia - Pipeline by Dicerna Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Dyslipidemia - Pipeline by Eccogene (Shanghai) Co Ltd, 2022
Dyslipidemia - Pipeline by Eli Lilly and Co, 2022
Dyslipidemia - Pipeline by Esperion Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Genu Pharma Co Ltd, 2022
Dyslipidemia - Pipeline by Gilead Sciences Inc, 2022
Dyslipidemia - Pipeline by Golden Biotechnology Corp, 2022
Dyslipidemia - Pipeline by Guangzhou Jiayue Pharmaceutical Technology Co Ltd, 2022
Dyslipidemia - Pipeline by Halo Therapeutics Ltd, 2022
Dyslipidemia - Pipeline by Handok Inc, 2022
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Dyslipidemia - Pipeline by HK inno.N Corp, 2022
Dyslipidemia - Pipeline by Huons Co Ltd, 2022
Dyslipidemia - Pipeline by Ildong Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Inovio Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Inversago Pharma Inc, 2022
Dyslipidemia - Pipeline by Japan Tobacco Inc, 2022
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Jenrin Discovery Inc, 2022
Dyslipidemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Dyslipidemia - Pipeline by JW Pharmaceutical Corp, 2022
Dyslipidemia - Pipeline by Korea United Pharm Inc, 2022
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Kowa Co Ltd, 2022
Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Kyttaro Ltd, 2022
Dyslipidemia - Pipeline by Kyung Dong Co Ltd, 2022
Dyslipidemia - Pipeline by Les Laboratoires Servier SAS, 2022
Dyslipidemia - Pipeline by Liid Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by LipimetiX Development Inc, 2022
Dyslipidemia - Pipeline by Lyndra Therapeutics Inc., 2022
Dyslipidemia - Pipeline by Madrigal Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, 2022
Dyslipidemia - Pipeline by MD Healthcare Inc, 2022
Dyslipidemia - Pipeline by Mochida Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Navipharm Co Ltd, 2022
Dyslipidemia - Pipeline by NewAmsterdam Pharma BV, 2022
Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, 2022
Dyslipidemia - Pipeline by Nissan Chemical Corp, 2022
Dyslipidemia - Pipeline by NorthSea Therapeutics BV, 2022
Dyslipidemia - Pipeline by NovalGen Ltd, 2022
Dyslipidemia - Pipeline by Novartis AG, 2022
Dyslipidemia - Pipeline by Nubiyota LLC, 2022
Dyslipidemia - Pipeline by NuSirt Biopharma Inc, 2022
Dyslipidemia - Pipeline by Omeros Corp, 2022
Dyslipidemia - Pipeline by Orient Pharma Co Ltd, 2022
Dyslipidemia - Pipeline by Pharmena SA, 2022
Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Rivus Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Saliogen Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Sequor Pharmaceuticals LLC, 2022
Dyslipidemia - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Dyslipidemia - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
Dyslipidemia - Pipeline by Sirnaomics Ltd, 2022
Dyslipidemia - Pipeline by SJT Molecular Research SL, 2022
Dyslipidemia - Pipeline by Staten Biotechnology BV, 2022
Dyslipidemia - Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Dyslipidemia - Pipeline by Sveikatal Inc, 2022
Dyslipidemia - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Dyslipidemia - Pipeline by Tetranov International Inc, 2022
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, 2022
Dyslipidemia - Pipeline by Viking Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Yooyoung Pharm Co Ltd, 2022
Dyslipidemia - Pipeline by Yungjin Pharm Co Ltd, 2022
Dyslipidemia - Pipeline by Zydus Lifesciences Ltd, 2022
Dyslipidemia - Dormant Projects, 2022
Dyslipidemia - Discontinued Products, 2022
List of Figures
Number of Products under Development for Dyslipidemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security